Mettler-Toledo/$MTD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mettler-Toledo
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
- Ticker
- $MTD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 16,600
- Headquarters
- Greifensee, Switzerland
- Website
- www.mt.com
Mettler-Toledo Metrics
BasicAdvanced
$34B
37.76
$44.45
1.19
-
Price and volume
Market cap
$34B
Beta
1.19
52-week high
$1,728.66
52-week low
$1,023.05
Average daily volume
197K
Financial strength
Current ratio
1.122
Quick ratio
0.66
Long term debt to equity
159.503
Total debt to equity
164.701
Interest coverage (TTM)
17.13%
Profitability
EBITDA (TTM)
1,273.109
Gross margin (TTM)
60.26%
Net profit margin (TTM)
21.91%
Operating margin (TTM)
28.74%
Effective tax rate (TTM)
17.47%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
21.00%
Return on equity (TTM)
-736.36%
Valuation
Price to earnings (TTM)
37.759
Price to revenue (TTM)
8.25
Price to book
2,622.25
Price to tangible book (TTM)
-34.16
Price to free cash flow (TTM)
39.476
Free cash flow yield (TTM)
2.53%
Free cash flow per share (TTM)
42.512
Growth
Revenue change (TTM)
6.91%
Earnings per share change (TTM)
12.53%
3-year revenue growth (CAGR)
1.49%
10-year revenue growth (CAGR)
5.48%
3-year earnings per share growth (CAGR)
3.76%
10-year earnings per share growth (CAGR)
13.12%
What the Analysts think about Mettler-Toledo
Analyst ratings (Buy, Hold, Sell) for Mettler-Toledo stock.
Analyst projections of the future price of Mettler-Toledo stock.
Bulls say / Bears say
Second-quarter organic sales grew 4% in local currency and adjusted EPS rose 14%; management raised its full-year sales and earnings outlook. This points to improving demand and operating leverage. (Mettler-Toledo)
Service sales grew 7% organically in the second quarter, outpacing product sales growth of 3%. A growing service business can provide steadier revenue alongside instrument sales. (SEC)
China sales grew 9% organically in the second quarter, while emerging markets outside China grew at a high-single-digit rate. Management sees US biopharma onshoring as a further source of instrument demand over the next few years. (The Motley Fool)
Mettler-Toledo’s premium valuation may leave little room for disappointment: Redburn argued that its share price was high relative to its growth outlook and initiated coverage with a Sell rating. A lower-than-expected growth rate could therefore weigh on the shares. (Investing.com)
Competition could make it harder to sustain premium pricing. Redburn said competitors are narrowing product-quality gaps, particularly in weighing and laboratory instruments, while core markets are growing at only about 3%–4% a year. (Investing.com)
Underlying growth remains moderate: organic local-currency sales rose 3% in the first half, and the Americas were flat. Management’s full-year organic growth outlook of 3%–4% leaves execution dependent on a gradual recovery in customer demand. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Mettler-Toledo Financial Performance
Revenues and expenses
Mettler-Toledo Earnings Performance
Company profitability
Upcoming events
No upcoming events
Mettler-Toledo News
AllArticlesVideos
Funds containing Mettler-Toledo
AllUSDEURGBP
Fund name | Fund size | $MTD weighting |
|---|---|---|
L&G Clean Water$GLUG | $772M | 2.26% |
L&G Clean Water£GLGG | $772M | 2.26% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.32% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.32% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.50% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.